Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by Cwm LLC

Cwm LLC trimmed its position in Quest Diagnostics Incorporated (NYSE:DGXGet Rating) by 7.4% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,515 shares of the medical research company’s stock after selling 280 shares during the period. Cwm LLC’s holdings in Quest Diagnostics were worth $431,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Wagner Wealth Management LLC bought a new position in Quest Diagnostics in the second quarter worth about $27,000. Chilton Capital Management LLC bought a new position in Quest Diagnostics in the second quarter worth about $36,000. Win Advisors Inc. lifted its holdings in Quest Diagnostics by 44.1% in the second quarter. Win Advisors Inc. now owns 271 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares during the last quarter. Larson Financial Group LLC lifted its holdings in Quest Diagnostics by 1,096.6% in the second quarter. Larson Financial Group LLC now owns 347 shares of the medical research company’s stock worth $46,000 after acquiring an additional 318 shares during the last quarter. Finally, Eagle Bay Advisors LLC bought a new position in Quest Diagnostics in the second quarter worth about $47,000. 88.79% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Quest Diagnostics news, Director Timothy M. Ring sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $144.06, for a total transaction of $288,120.00. Following the completion of the sale, the director now directly owns 24,149 shares in the company, valued at approximately $3,478,904.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Quest Diagnostics news, Director Timothy M. Ring sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $144.06, for a total transaction of $288,120.00. Following the completion of the sale, the director now directly owns 24,149 shares in the company, valued at approximately $3,478,904.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Timothy M. Ring sold 2,025 shares of the firm’s stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $152.50, for a total value of $308,812.50. Following the sale, the director now owns 24,149 shares of the company’s stock, valued at $3,682,722.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,287 shares of company stock worth $8,925,320. 1.70% of the stock is currently owned by company insiders.

Quest Diagnostics Price Performance

Shares of Quest Diagnostics stock opened at $148.12 on Friday. The company’s 50-day moving average price is $150.94 and its two-hundred day moving average price is $138.73. The stock has a market cap of $16.87 billion, a PE ratio of 14.56 and a beta of 0.98. Quest Diagnostics Incorporated has a 52 week low of $120.40 and a 52 week high of $158.34. The company has a current ratio of 1.46, a quick ratio of 1.34 and a debt-to-equity ratio of 0.63.

Quest Diagnostics (NYSE:DGXGet Rating) last issued its quarterly earnings results on Thursday, October 20th. The medical research company reported $2.36 earnings per share for the quarter, topping analysts’ consensus estimates of $2.17 by $0.19. The firm had revenue of $2.49 billion for the quarter, compared to analysts’ expectations of $2.34 billion. Quest Diagnostics had a return on equity of 21.36% and a net margin of 12.00%. Quest Diagnostics’s revenue was down 10.4% on a year-over-year basis. During the same quarter last year, the business posted $3.96 EPS. As a group, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 9.85 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 1st. Shareholders of record on Wednesday, January 18th will be given a dividend of $0.66 per share. The ex-dividend date is Tuesday, January 17th. This represents a $2.64 dividend on an annualized basis and a yield of 1.78%. Quest Diagnostics’s payout ratio is presently 25.96%.

Wall Street Analysts Forecast Growth

DGX has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised their target price on shares of Quest Diagnostics from $129.00 to $140.00 and gave the stock a “hold” rating in a report on Friday, October 21st. Mizuho lifted their price target on Quest Diagnostics from $160.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, December 14th. Citigroup lowered Quest Diagnostics from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $145.00 to $125.00 in a report on Thursday, November 17th. William Blair reaffirmed an “outperform” rating on shares of Quest Diagnostics in a research note on Thursday, October 20th. Finally, StockNews.com raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $150.00.

Quest Diagnostics Profile

(Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Stories

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.